Citi downgraded Acorda Therapeutics, Inc. (NASDAQ: ACOR) from Buy to Neutral with a price target of $33.00 (from $37.00), saying ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE